The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitisMarco Carbone, George Mells, Douglas Thorburn et al.|Hepatology|2015Cited by 348
A disease-associated gene desert directs macrophage inflammation through ETS2Christina T. Stankey, James Lee, Christophe Bourges et al.|Nature|2024Cited by 139
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Christopher L. Bowlus et al.|Journal of Hepatology|2020Cited by 10
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 studyGideon M. Hirschfield, DE Jones, Pol Boudes et al.|Journal of Hepatology|2018Cited by 5
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIESStuart C. Gordon, Marlyn J. Mayo, Palak Trivedi et al.|Gastroenterology|2022Cited by 2